Posts tagged Congruence Therpeutics Inc.

Congruence Therapeutics Announces Close of Series A Extension, Bringing Total Round to Over US$65 Million

Congruence Therapeutics, announced today the close of an extension to its Series A financing, bringing the total amount raised to over US$65 million. This extension was led by new investor BDC Capital's Thrive Venture Fund, with participation from current investors Amplitude Ventures, Fonds de solidarité FTQ, OrbiMed, Investissement Quebec (IQ), SilverArc, and others.

NewsGuest UserMarch 16, 2023BIOOQuébecCongruence Therpeutics Inc., biotechnology, drug discovery

Congruence Therapeutics Inc. Announces US$50 million Series A Financing to Advance Platform Targeting Diseases of Protein Misfolding

Company founded in 2021 and led by Clarissa Desjardins, Ph.D., previously the founder and chief executive officer of Clementia Pharmaceuticals (now Ipsen). Kenneth J. Valenzano, Ph.D., joins as Chief Scientific Officer, adding to a team with domain experience in rare disease clinical development, computational and medicinal chemistry, and business development

NewsCatherine LamontagneFebruary 11, 2022Congruence Therpeutics Inc., Financing